Indaptus Therapeutics, Inc. (INDP)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -20 | -15 | ||||||
| Net profit | $m | -4 | -8 | -14 | -15 | -15 | -21 | -15 | -6 |
| EPS reported | $ | -21.58 | -6.97 | ||||||
| Operating cashflow per share | $ | -15.34 | -0.13 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -15.34 | -0.13 | ||||||
| Free cash flow | $m | -15 | -15 | ||||||
| Net debt | $m | -9 | -12 | ||||||
| Book value equity | $m | 3 | 11 | ||||||
| Book value per share | $ | 3.26 | 0.10 | ||||||
| Number of shares | m | 0.97 | 116.13 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.89 | 0.25 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -0.19 | -0.19 | ||||||
| EV/EBITDA LTM | x | 0.27 | 0.37 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -7.42% | -12.41% | ||||||
| FCF Yield | % | -527.25% | -540.04% | ||||||
| Quality | |||||||||
| ROE | % | -661.54% | -302.75% | ||||||
| ROIC | % | -6.29% | -1.30% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.41 | 0.49 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -2.70 | -1.02 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Indaptus Therapeutics, Inc. (INDP)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free